Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 1 week ago

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 1 week ago

New blog articles detected

  • Three Finalists Announced for the Inaugural Bloom Burton Award

    Annual Award to Recognize the Most Significant Contributor to Canada’s Healthcare Industry TORONTO, May 8, 2017 – Bloom Burton & Co. (“Bloom Burton”), Canada’s leading healthcare-specialized investment banking firm, is pleased to announce the three finalists for the inaugural Bloom Burton Award. The finalists are: Allen Eaves, Founder, President and CEO of STEMCELL Technologies: Anthony Giovinazzo...

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 2 weeks ago

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 2 weeks ago

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 2 weeks ago

New blog articles detected

  • Hamilton Thorne Announces Acquisition of Gynemed GmbH & Co.

    Click here to read the full press release. Source: Newswire – April 28, 2017 BEVERLY, MA and TORONTO, ON — (April 28, 2017) – Hamilton Thorne Ltd. (TSX VENTURE: HTL) (“Hamilton Thorne” or the “Company”), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 1 month ago

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 3 months ago

New blog articles detected

  • Q4 and Annual Share Price Performance in 2016 – Part 1

    For the analysis of the 2016 share price performance for the Canadian healthcare sector, there were 115 companies starting 2016 with share prices of $0.10 or higher. Twelve of these companies were no longer in the sector by the end of 2016, with six lost through acquisition/merger transactions. For the remaining 103 companies, the sector […] The post Q4 and Annual Share Price Performance in 2016 –...

  • Apollo shrugged: Don’t Cross That Line – Contradictions in Provincial Pharmacare

    Don’t Cross That Line – Contradictions in Provincial Pharmacare I’m in the middle of moving from Nova Scotia to Prince Edward Island and all that entails. I am aware that we’re fiercely proud of our provincial cultural differences here in the Maritimes (try debating who has the best lobster) so I expect a few things […] The post Apollo shrugged: Don’t Cross That Line – Contradictions in Provincial...

  • Q3 2016 – Share Price Performance – Part 3

    Tier 2 Canadian Healthcare Companies – better performance than the Tier 1 companies In this blog, I am going to comment on the Q3 and 9-month 2016 share price performance of the group of 57 companies with share prices of between $0.10 and $0.99 to start 2016 (DiagnoCure is not included). Advancers outnumbered decliners by […] The post Q3 2016 – Share Price Performance – Part 3 appeared first on Bl...

  • Q3 2016 – Share Price Performance – Part 2

    Tier 1 Canadian Healthcare Companies – a very healthy bounce back In this blog, I am going to comment on the Q3 and 9-month performances of the group of 54 companies with share prices of $1.00 or more to start 2016 (Stellar Biotechnologies, Prism Medical and Transition Therapeutics dropped from assessment). Advancers outnumbered decliners by […] The post Q3 2016 – Share Price Performance – Part 2 ...

  • Q3 2016 – Share Price Performance – Part 1

    Improved, positive performance in Q3 Overall, Q3 2016 share price performance in the sector was much better than in Q2 for the companies starting 2015 with share prices of $0.10 or higher. Two more companies have been deleted from the analysis in Q3 – Transition Therapeutics was acquired by OPKO Health and Prism Medical was […] The post Q3 2016 – Share Price Performance – Part 1 appeared first on ...

  • Q4 and Annual Share Price Performance in 2016 – Part 3

    Tier 2 Canadian Healthcare Companies – same as Tier 1, not a good year In this blog, I am going to comment on the Q4 and annual 2016 share price performances of the group of 52 companies which ended 2016 in Tier 2 (there were 58 companies with share prices of $1.00 or more to […] The post Q4 and Annual Share Price Performance in 2016 – Part 3 appeared first on Bloom Burton.

  • Q4 and Annual Share Price Performance in 2016 – Part 2

    Tier 1 Canadian Healthcare Companies – not a good year In this blog, I am going to comment on the Q4 and 2016 annual performances of the group of 51 companies which ended 2016 in Tier 1 (there were 57 companies with share prices of $1.00 or more to start 2016). Q4 2016 Performance Decliners […] The post Q4 and Annual Share Price Performance in 2016 – Part 2 appeared first on Bloom Burton.

Bloom Burton & Co.

Category: Content
Type: Blog Article

Generated 8 months ago

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in